157 related articles for article (PubMed ID: 34910356)
21. Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Kaku K; Haneda M; Sakamaki H; Yasui A; Murata T; Ustyugova A; Chin R; Hirase T; Shibahara T; Hayashi N; Kansal A; Kaspers S; Okamura T
Clin Ther; 2019 Oct; 41(10):2021-2040.e11. PubMed ID: 31561882
[TBL] [Abstract][Full Text] [Related]
22. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.
Ramos M; Men P; Wang X; Ustyugova A; Lamotte M
Cost Eff Resour Alloc; 2021 Aug; 19(1):46. PubMed ID: 34348729
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
Reifsnider OS; Kansal AR; Franke J; Lee J; George JT; Brueckmann M; Kaspers S; Brand SB; Ustyugova A; Linden S; Stargardter M; Hau N
ESC Heart Fail; 2020 Dec; 7(6):3910-3918. PubMed ID: 32909680
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
[TBL] [Abstract][Full Text] [Related]
26. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Kristensen MM; Ejskjaer N
Diabetes Ther; 2022 Mar; 13(3):489-503. PubMed ID: 35187628
[TBL] [Abstract][Full Text] [Related]
27. Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
Cessario J; Pierre-Louis V; Wahl J; Li Z
Pharmacol Rep; 2021 Jun; 73(3):858-867. PubMed ID: 33555600
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.
Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
J Comp Eff Res; 2022 Jan; 11(1):29-37. PubMed ID: 34841893
[No Abstract] [Full Text] [Related]
29. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Monteiro P; Bergenstal RM; Toural E; Inzucchi SE; Zinman B; Hantel S; Kiš SG; Kaspers S; George JT; Fitchett D
Age Ageing; 2019 Nov; 48(6):859-866. PubMed ID: 31579904
[TBL] [Abstract][Full Text] [Related]
30. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes.
Zupa MF; Codario RA; Smith KJ
J Comp Eff Res; 2021 Oct; 10(15):1133-1141. PubMed ID: 34490786
[No Abstract] [Full Text] [Related]
32. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
33. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
[TBL] [Abstract][Full Text] [Related]
35. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom.
Ramos M; Gerlier L; Uster A; Muttram L; Frankel AH; Lamotte M
J Med Econ; 2024; 27(1):777-785. PubMed ID: 38758099
[TBL] [Abstract][Full Text] [Related]
37. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Lee WC; Samyshkin Y; Langer J; Palmer JL
J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
[TBL] [Abstract][Full Text] [Related]
38. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Scheen AJ; Piérard L; Krzesinski JM; Paquot N
Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Abdul-Ghani M; DeFronzo RA; Del Prato S; Chilton R; Singh R; Ryder REJ
Diabetes Care; 2017 Jul; 40(7):813-820. PubMed ID: 28637886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
